Baldwin 10-Q Details $81.6M Q3 Loss, $147M Tax Benefit and HSR Clearance for $32.50 Take-Private
BWIN has more than doubled off its 52-week low of $15.88 on light trading volume (0.4× avg).
Summary
Baldwin's Q3 10-Q fills in the $81.6M net loss and 47% adjusted EBITDA growth already reported, and adds a $147.0M tax benefit, a $144.6M TRA liability and confirmation that the HSR waiting period for the $32.50-per-share take-private expired November 4.
Key Events · Earnings and Guidance · BWIN
-
Q3 Net Loss Widens to $81.6M
GAAP net loss was $81.6 million, or $0.63 per diluted share, versus a $30.2 million loss a year earlier, on revenue up 31% to $480.3 million.
-
Organic Growth Only 6%
Of the $113.2 million increase in commissions and fees, $91.7 million came from acquisitions; organic revenue growth was 6% for the quarter.
-
Tax Valuation Allowance Released
A $167.1 million valuation allowance release, prompted by $142.2 million of deferred tax liabilities from the CAC Group and Obie deals, drove a $147.0 million nine-month income tax benefit.
-
TRA Liability of $144.6M Booked
Baldwin recognized a $144.6 million Tax Receivable Agreement liability, including $130.0 million charged to other operating expense; the TRA Amendment caps payments at up to $298.5 million on a go-private close.
Analysis · BWIN · Finance
The headline numbers were already out on October 27 and in today's 8-K, but the full 10-Q adds the pieces that actually move the story. A $167.1M deferred-tax valuation allowance release, driven by the CAC Group and Obie acquisitions, produced a $147.0M nine-month tax benefit and flipped the balance sheet to a small net deferred tax liability. That same reassessment forced Baldwin to book a $144.6M Tax Receivable Agreement liability, $130.0M of which hit other operating expense — a real future cash obligation to LLC members, though the TRA Amendment caps it at up to $298.5M if the go-private closes. Operationally, revenue rose 31% to $480.3M but organic growth was only 6%, with acquisitions doing the heavy lifting. With the HSR waiting period cleared on November 4, the remaining gating item for the $32.50-per-share cash deal is the stockholder vote, and the shares already trade near that price.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BWIN was trading at $32.15 on NASDAQ in the Finance sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $15.88 to $32.71. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.